Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted) (2016 - 2025)

Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$2.39 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 2555.56% to -$2.39 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.73, a 1030.3% decrease, with the full-year FY2025 number at -$3.74, down 1033.33% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$2.39 in Q4 2025 for Vanda Pharmaceuticals, down from -$0.38 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for VNDA hit a ceiling of $0.17 in Q2 2021 and a floor of -$2.39 in Q4 2025.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.17 across 5 years, with a median of -$0.02 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1400.0% in 2021 and later plummeted 3878.18% in 2024.
  • Tracing VNDA's EPS (Weighted Average and Diluted) over 5 years: stood at $0.12 in 2021, then rose by 0.0% to $0.12 in 2022, then tumbled by 141.67% to -$0.05 in 2023, then plummeted by 80.0% to -$0.09 in 2024, then tumbled by 2555.56% to -$2.39 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VNDA at -$2.39 in Q4 2025, -$0.38 in Q3 2025, and -$0.46 in Q2 2025.